Lilly commits $2.1 billion to two Indiana plants weeks after Mounjaro approval

In May 2022, Eli Lilly said it would spend $2.1 billion to put up two factories in Boone County, Indiana, betting that it needed more of its own manufacturing capacity ^[2][3]. The plants were slated for the LEAP Lebanon Innovation and Research District, northwest of Indianapolis ^[3].

Lilly said the pair of facilities would let it make more active pharmaceutical ingredients — the drug substance itself — and would also handle newer categories such as genetic medicines. Which products would be made there was not specified at the time ^[3]. The company put the hiring at up to 500 corporate jobs, with roughly 1,500 temporary construction slots during the build ^[3].

The announcement arrived about two weeks after the Food and Drug Administration cleared Mounjaro (tirzepatide) for type 2 diabetes ^[3]. Lilly had secured 17 drug approvals over the previous eight years and was expecting as many as four more launches within two years, a list that included donanemab for Alzheimer's disease and pirtobrutinib for cancer; Wall Street sales estimates for those and for Mounjaro ran around $3 billion or higher ^[3]. Capital spending had been about $1.4 billion in 2020 and $1.3 billion in 2021, according to the company's annual filing at the time ^[3]. Lilly had also set aside $2.5 billion for sites in and around Indianapolis over five years and was building a $470 million plant in North Carolina ^[3].

The same site kept getting bigger

Three more rounds followed at Lebanon: $1.6 billion in April 2023, $5.3 billion in May 2024, and $4.5 billion for a research and clinical-supply complex called the Lilly Medicine Foundry, for a running total above $13 billion ^[2]. The May 2024 tranche alone raised the site's budget from $3.7 billion to $9 billion and was described as a way to boost production of active ingredients for Zepbound (tirzepatide) injection and Mounjaro (tirzepatide) injection ^[1]. Lilly said that round would bring 200 more full-time jobs, for about 900 once the site runs at full capacity, plus more than 5,000 construction jobs over the building period ^[1].

Lilly has said the manufacturing push began in 2020, driven by tirzepatide research results, and that it spent the money before regulators acted — Mounjaro was approved in 2022 and Zepbound in 2023. The company calls those two drugs the only approved medicines that activate both the GIP and GLP-1 incretin hormone receptors ^[1].

Why it matters for patients

How much active ingredient a company can make sets how much of a drug it can sell. Lilly has said orders for Mounjaro, Zepbound and other medicines once ran ahead of what it could supply, and that the pressure has since eased, with pharmacies receiving much of what they ordered ^[2]. The Lebanon work is aimed at that limit.

Prices are a separate question. Nothing in these announcements says the added capacity will change what patients or insurers pay for Mounjaro or Zepbound, and no pricing commitment tied to the plants has been disclosed ^[1][2].

The calendar matters too. Because Lebanon production is not expected to start until near the end of 2026 and to build up through 2028, the capacity could not have relieved shortages in 2022 or 2023 ^[1].

What happens next

Lilly expects Lebanon to begin producing medicines late in 2026, with operations scaling through 2028 ^[1]. The Medicine Foundry — a standalone complex of seven main buildings on roughly 200 added acres — is due to open in late 2027; Lilly said it has not yet decided where on the site it will go ^[2]. The foundry is meant for research and for making clinical-trial supplies, not for full-scale commercial production, and any new manufacturing methods developed there would move to Lilly's other plants ^[2].

Indiana has pledged road, water and utility work, including at least $45 million allocated by the state's economic development corporation for the Lilly portion of LEAP. Citizens Energy Group and Lebanon Utilities won approval for $200 million and $125 million in state loans toward a water extension expected to deliver up to 25 million gallons a day ^[2].

As of the foundry announcement, Lilly was the only company that had committed to the district, which state officials say has attracted $18 billion in pledged capital across 2,300 acres since 2022 ^[2].